ClinicalTrials.gg
RecruitingNCT06441123TatLatUpdated Feb 24, 2025

Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein

An observational study in HIV Infections, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by University Hospital, Montpellier · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
24
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 278 studies in HIV Infections with a site in France — 19 open to participants now, 27 under way, 5 of them phase 3. HIV Infections · France.

Planned enrollment
56th of 59
24 · median 200
Started
2025
with 3 others
Observational
59 of 278
13 open now
Primary completion
2027-02
later than 17 of 26 live
Registered
265th of 278
by date

Among the 278 studies in HIV Infections with a site in France, this one is the 56th largest by planned enrollment of the 59 observational ones that give a count, is one of 4 that started in 2025, is one of 59 observational ones, reaches primary completion later than 17 of the 26 other live ones, and was the 265th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

19 of the 278 studies in HIV Infections with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 278 studies in HIV Infections with a site in France, or all of them as a file.
02

Study summary

Antiretroviral therapy (ART) prevents HIV from multiplying. However, if people living with HIV stop taking ART, the virus quickly reappears in their blood due to the random activation of hidden infected cells. These hidden cells contain HIV that is not active and do not produce the virus. These cells are a major challenge in finding a cure for HIV.

One of the most promising ways to get rid of these hidden infected cells is by activating them with special drugs called latency-reversing agents (LRAs). This process, known as the "shock-and-kill" strategy, involves waking up the hidden virus ("shock" phase) so that it can be destroyed by the body's immune system or by the virus itself ("kill" phase).

Investigators are developing new LRAs that target and activate a viral protein called Tat, which is necessary for the virus to start producing again and for reversing its dormant state.The lead compound, named D10, is the first of its kind to target the Tat protein. This compound has been patented and has shown activity in activating the virus in lab-grown cells. Now, investigators need to test its effectiveness on real target cells from people living with HIV.

Read the detailed description

20 ml of blood (5 tubes of 4 ml each) will be collected from 24 people living with HIV who are on ART. The inclusion criteria for this study are: being HIV-positive, having an undetectable viral load for more than 12 months, and having a history of very low T-CD4 counts (nadir \< 200 cells/mm³).

In the lab, investigators will isolate immune cells (PBMCs) from the blood using a special technique. These cells will then be placed in small wells and treated with LRAs for 18-20 hours. Investigators will measure the virus produced in the cell supernatant using two methods: q-RT-PCR for viral RNA and p24 ELISA for viral protein. The results will be analyzed using conventional statistical methods.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV-1
  • Tat
  • latency
  • latency reversing agents
  • transcription
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target population is aviremic HIV-positive individuals, with no age criterion, having a long history of HIV infection (nadir \< 200 CD4/µL

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged 18 years or older
  • -positive
  • On ART (antiretroviral therapy)
  • HIV-1 RNA undetectable for more than 12 months
  • Nadir \< 200/µL

Exclusion criteria

Exclusion Criteria:

  • Lack of antiretroviral treatment
  • treatments
  • History of cancer less than 5 years old
  • Pregnant or breast-feeding women
  • Persons protected by law (under guardianship or curators), persons under court protection
  • Participating in another research project with an ongoing exclusion period
  • Refusal to participate in research
  • Subject not affiliated to a social security scheme, or not benefiting from such a scheme.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
24 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • BiologicalBlood Sampling

    20 ml of blood (5 tubes of 4 ml) will be collected once.

06

What researchers measure

Primary outcomes

  1. Quantity of p24 in the cell supernatant 18-20 hours after the addition of the LRAs (Latency Reversing Agents)

    Viral production is considered significant if the signal obtained from the p24 ELISA of these supernatants is more than twice the background observed in the absence of LRA

    Time frame: INCLUSION VISIT

Secondary outcomes

  1. Quantity of viral RNA in the cell supernatant 18-20 hours after the addition of LRAs.

    quantity of viral RNA in the cell supernatant 18-20 hours after the addition of LRAs.

    Time frame: INCLUSION VISIT

  2. Measure the effective dose of D10 to reverse the latency of latent HIV-infected PBMCs

    effective dose of D10 to reverse the latency of latent HIV-infected PBMCs

    Time frame: INCLUSION VISIT

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.

Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 24 months is below that.

Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 4, 2024
StartActual
Feb 10, 2025
Primary completionEst.
Feb 10, 2027
CompletionEst.
Feb 10, 2027
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06441123
Collaborators
Centre National de la Recherche Scientifique, France, Université Montpellier
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Feb 10, 2025
Primary completion
Feb 10, 2027 (estimated)
Completion
Feb 10, 2027 (estimated)
Last update
Feb 24, 2025

Study contacts

Alain MAKINSON, Pr
Contact
a-makinson@chu-montpellier.fr
04 67 33 83 40
Bruno BEAUMELLE
Contact
bruno.beaumelle@irim.cnrs.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion